b73

Albonoursin is used as an antibacterial cyclic dipeptide.

UCB7362 (GLXC-26743) is an orally available and potent plasmepsin X (PMX) inhibitor with anti-malarial activity.UCB7362 inhibits parasite reproduction.

UCB7362 hydrochloride (UCB7362 HCl) is an orally active plasmepsin X (PMX) inhibitor (IC50: 7 nM) with antimalarial activity that inhibits parasite growth.

S-8510 phosphate is an agonist of inverse Benzodiazepine (BDZ) receptor(Kis of 34.6 nM, 36.2 nM for –GABA and +GABA respectively).

Atomoxetine (HSDB 7352) is a selective norepinephrine inhibitor that may cause an increase in blood pressure by increasing norepinephrine concentrations in peripheral sympathetic neurons .Atomoxetine is a highly selective antagonist of presynaptic norepinephrine transporters with little or no affinity for other norepinephrine receptors or other neurotransmitter transporters or receptors, but has little or no affinity for 5- hydroxytryptamine transporter. Atomoxetine selectively inhibits reuptake of norepinephrine and can be used to treat adolescents with ADHD and chronic tics.

CAB7-3 is an orally effective HBV capsid assembly modulator that demonstrates excellent antiviral potency. It inhibits HBVDNA with an EC50 of 70 nM and has a CC50 of 32.3 μM. The compound exhibits significant anti-HBV activity across various cell models, with EC50 values of 70 μM in HBV-integrated HepDES19 cells, 1 nM in tetracycline-induced HepAD38 cells, and 2 nM in HBV-infected HLCZ01 cells. In vivo, CAB7-3 effectively reduces hepatic HBV core protein levels and suppresses viral replication. It shows good drug-like properties and safety, making it suitable for hepatitis B virus research.

S-8510 is a GABA-A receptor inverse agonist. S-8510 selectively potentiated pentylenetetrazol-induced convulsion without affecting minimal electroconvulsive shock- or strychnine-induced convulsion in ddY mice. S-8510 ameliorated memory impairment induced

SB-737050A, a 5-HT antagonist, is used potentially for the treatment of schizophrenia.

Timigutuzumab is a glyco-optimized monoclonal antibody targeting the human epidermal growth factor receptor 2 (ErbB2/HER2). Through glyco-engineering (typically afucosylation), the antibody's Fc region exhibits enhanced binding affinity for the FcγRIIIa receptors on immune effector cells, such as natural killer (NK) cells. This optimization significantly boosts Antibody-Dependent Cell-mediated Cytotoxicity (ADCC), enabling potent tumor cell lysis even in cases with low HER2 expression levels. Timigutuzumab is designed to overcome resistance to conventional anti-HER2 therapies and provide an improved therapeutic option for solid tumors.

SB-734117 inhibits productive replication of several HCMV strains. SB-734117 exhibited polypharmacology and was an inhibitor of several proteins from the AGC and CMCG kinase groups.

Anti-CD19 Antibody (IKS03 Naked Antibody) is an antibody targeting CD19 and can be used to generate the ADC IKS03. Anti-CD19 Antibody (IKS03 Naked Antibody) can be used for oncology research.

B7-33 is a single-chain relaxin analog and a selective agonist for relaxin receptor 1 (RXFP1). It binds to RXFP1 and preferentially activates the pERK pathway in cells expressing RXFP1, rather than cAMP. B7-33 serves as an antifibrotic agent and provides cardioprotective effects.